The PROGRESS trial three years later: time for a balanced report of effectiveness.
Wennberg
Richard
R
Department of Medicine, University of Toronto, University Health Network, Toronto, ON, Canada M5T 2S8. Richard.Wennberg@uhn.on.ca
Zimmermann
Camilla
C
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003627:Data Interpretation, Statistical; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007190:Indapamide / Q000627:therapeutic use*; D020913:Perindopril / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000592:standards; D018570:Risk Assessment; D012307:Risk Factors; D055502:Secondary Prevention; D020521:Stroke / Q000517:prevention & control*
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007190:Indapamide; D020913:Perindopril